Search - tctmd.com

Displaying 61 - 80 of 161

Sort: Relevancy | Date

Presentation LINC 2019

Debate: Surgical Reconstruction is Still the Gold Standard for the Common Femoral Artery

Presenter: Brian G. DeRubertis

January 25, 2019

Presentation LINC 2019

Femoral Popliteal DVT

Presenter: Robert Lookstein

January 25, 2019

News Daily News

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

L.A. McKeown

January 25, 2019

News Daily News

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

L.A. McKeown

January 23, 2019

News Daily News

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

Caitlin E. Cox

January 10, 2019

News Daily News

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

L.A. McKeown

December 18, 2018

News Daily News

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

L.A. McKeown

December 07, 2018

Presentation Controversies and Advances 2018

Management of Severe AS Patient with Poor Access – Surgical or Percutaneous?

Presenter: Ted Feldman

November 16, 2018

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

News Conference News VIVA 2018

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

L.A. McKeown

November 09, 2018

News Daily News

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Caitlin E. Cox

October 05, 2018

News Industry News

Veryan Medical receives PMA approval for BioMimics 3D

October 05, 2018

Presentation TCT Abstracts Posters 2018

Occurrence of significant mirror lesions in the lower extremity arterial disease.

Presenter: Aleksandra Kolarczyk-Haczyk1

September 25, 2018

News Conference News TCT 2018

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

Todd Neale

September 24, 2018

News Conference News TCT 2018

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

Todd Neale

September 22, 2018

Presentation TCT 2018

IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions

Presenter: William A. Gray

September 22, 2018

Presentation CHIP Seattle 2018

Complications and Management of Femoral Access

Presenter: Curtiss T. Stinis

August 11, 2018

News Daily News

No Benefits, Higher Costs With IVC Filters in Catheter-Directed Thrombolysis for DVT

Michael O'Riordan

July 23, 2018

Presentation

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

May 08, 2018

News Daily News

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

L.A. McKeown

May 08, 2018

Advertisement

Debate: Surgical Reconstruction is Still the Gold Standard for the Common Femoral Artery

Femoral Popliteal DVT

IN.PACT Admiral Data Show No Death Difference at 5 Years for Paclitaxel DCBs vs PTA in Femoropopliteal Disease

Industry, Investigators Push Back With Patient-Level Data Showing No Increased Death From Paclitaxel-Based PAD Therapies

Guidelines for Peripheral Interventions Often Built on Shaky Foundation

New Appropriate Use Criteria for Peripheral Artery Interventions: A Multisociety Collaboration

Signal of Late Deaths With Paclitaxel-Coated DCBs and Stents for PAD Warrants Urgent Review, Authors Say

Management of Severe AS Patient with Poor Access – Surgical or Percutaneous?

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

Now You See Them, Now You Don’t: Bioresorbable Devices Target Large-Bore Closures and PE Prevention

FDA Approves BioMimics 3D Stent for Femoropopliteal Artery Disease

Veryan Medical receives PMA approval for BioMimics 3D

Occurrence of significant mirror lesions in the lower extremity arterial disease.

Eluvia Gains FDA Approval Just Days After IMPERIAL Results Released

IMPERIAL: Eluvia Tops Zilver PTX in Battle of DES in Femoropopliteal Disease

IMPERIAL: A Randomized Trial of Drug-Eluting Stents for Treatment of Femoropopliteal Artery Lesions

Complications and Management of Femoral Access

No Benefits, Higher Costs With IVC Filters in Catheter-Directed Thrombolysis for DVT

12-Month Results From First-in-Human Randomized Study of Ranger DCB for Femoropopliteal Treatment

RANGER-SFA Data Support Another Paclitaxel-Coated Balloon for Superficial Femoral Artery Disease

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content